Targeted Lung Denervation (TLD)

DEVICE4 trials

Sponsors

Nuvaira, Inc.

Conditions

AsthmaCOPDChronic Obstructive Pulmonary Disease

Unknown Phase

Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma

TerminatedNCT02872298

Nuvaira, Inc.Asthma

Start: 2017-12-22End: 2020-04-06Updated: 2022-04-12

Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

WithdrawnNCT03213080

Nuvaira, Inc.COPD

Start: 2017-12-31End: 2021-09-30Updated: 2019-02-18

Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruitingNCT03639051

Nuvaira, Inc.COPD

Start: 2019-05-23End: 2028-09-30Updated: 2024-11-14

Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

RecruitingNCT07051707

Nuvaira, Inc.Chronic Obstructive Pulmonary Disease, COPD

Start: 2026-02-24End: 2029-10-31Target: 200Updated: 2026-04-28

Related Papers

Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).

2025-12-013 citations

Pre-treatment lung function decline stabilizes up to 3 year after targeted lung denervation in COPD

2020-09-072 citations

Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).

2020-02-1320 citations

Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial

American Journal of Respiratory and Critical Care Medicine2019-08-1268 citations